查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867502

花生过敏治疗：全球市场份额和排名、总收入和需求预测（2025-2031年）

Peanut Allergy Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 126 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球花生过敏药物市场规模估计为 7.52 亿美元，预计到 2031 年将达到 15.95 亿美元，在预测期（2025-2031 年）内复合年增长率为 11.4%。

花生过敏的治疗涵盖一系列旨在解决花生蛋白引发的异常免疫反应的预防和治疗方法。这些治疗方法包括口服免疫疗法（OIT）、皮下免疫疗法以及新兴的生物製药和小分子药物，旨在提高患者对花生的耐受性，并降低过敏反应的频率和严重程度。花生过敏是全球最常见且可能危及生命的食物过敏之一，影响着从儿童到​​成人的广泛人群，严重影响患者的生活质量，并给社会带来沉重的经济负担。随着精准医疗和免疫调节技术的进步，花生过敏的治疗正从单纯的规避策略发展到积极的免疫调节，从而推动了临床实践的快速发展和市场需求的增长。

近年来，全球食品安全意识的提高以及花生过敏患者数量的增加，为花生过敏治疗市场创造了巨大的成长机会。各国政府和监管机构逐步加强了扶持政策，促进了免疫核准和创新生物製药的临床审批和市场推广。医疗技术的进步推动了口服免疫疗法和个人化治疗方法的成熟，显着提高了患者的依从性和安全性，加速了市场需求的成长。多家生物製药公司正在加大研发投入，积极开发差异化产品和联合治疗，从而建立了多元化且高附加价值的竞争格局。然而，儘管市场潜力巨大，花生过敏治疗领域仍面临许多挑战。对治疗过程中过敏反应和安全性的担忧限制了患者的接受度，并减缓了市场渗透率。医疗资源的区域差异影响了治疗的可近性和覆盖范围。此外，治疗方法高成本且管理复杂，对医保报销和患者的负担能力带来了挑战。缺乏标准化的治疗通讯协定和监管差异进一步加剧了跨境产品上市的困难。为确保市场稳定成长，企业必须谨慎平衡创新突破与风险管理。下游对花生过敏药物的需求正转向精准和全面的护理管理。早期筛检技术的普及和公众意识的提高将使更多潜在患者能够及时获得诊断和干预，从而促进免疫疗法的更广泛应用。加强初级保健医生、过敏专科医生和学校健康课程之间的合作将有助于实现个人化的长期治疗管理。对安全便捷产品的需求将持续增长，而数位化健康解决方案和远端医疗支援将成为提高治疗依从性和监测治疗效果的重要工具。总体而言，市场正在发展成为一个涵盖诊断、治疗和后续护理的综合生态系统。

本报告旨在按地区/国家、类型和分销管道对全球花生过敏药物市场进行全面分析，重点关注总销售额、市场份额和主要企业的排名。

花生过敏药物市场规模、估算和预测均以销售收入为指标，以2024年为基准年，并包含2020年至2031年的历史数据和预测数据。我们的定量和定性分析将帮助读者制定花生过敏药物的业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Viatris
  • Bayer
  • UCB Pharma
  • J & J
  • Perrigo
  • GSK
  • Kaleo
  • Amneal Pharma
  • ALK Abello
  • Aimmune Therapeutics
  • HUAPONT Pharm
  • Allergy Therapeutics
  • ASIT Biotech
  • Sanofi
  • DBV Technologies
  • HAL Allergy
  • Intrommune Therapeutics

按类型分類的细分市场

  • 肾上腺素注射
  • 抗组织胺药物
  • 口服免疫疗法
  • 其他的

分销通路细分

  • 医院药房
  • 零售药房
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Peanut Allergy Therapeutics was estimated to be worth US$ 752 million in 2024 and is forecast to a readjusted size of US$ 1595 million by 2031 with a CAGR of 11.4% during the forecast period 2025-2031.

Peanut Allergy Therapeutics refer to a range of preventive and treatment approaches designed to address the immune system's abnormal response triggered by peanut proteins. These therapies include oral immunotherapy (OIT), subcutaneous immunotherapy, and emerging biologics and small molecule drugs, aiming to increase patients' tolerance to peanuts and reduce the frequency and severity of allergic reactions. As one of the most common and potentially life-threatening food allergies globally affecting both children and adults, peanut allergy significantly impacts patient quality of life and imposes economic burdens on society. With advancements in precision medicine and immune modulation technologies, peanut allergy treatment is evolving from mere avoidance strategies to active immune regulation, driving rapid growth in clinical practice and market demand.

In recent years, rising global awareness of food safety and the expanding population of peanut allergy patients have created significant growth opportunities for the peanut allergy therapeutics market. Governments and regulatory bodies worldwide have progressively improved support policies, facilitating clinical approval and market introduction of immunotherapies and innovative biologics. Advances in medical technologies have enhanced the maturity of oral immunotherapy and personalized treatment regimens, markedly improving patient compliance and safety, thereby accelerating market demand. Multiple biopharmaceutical companies have increased R&D investments, actively developing differentiated products and combination therapies, contributing to a diversified and high-value competitive landscape.Despite vast market potential, the peanut allergy therapeutics sector faces several challenges. Allergic reactions and safety concerns during treatment limit patient acceptance and slow adoption rates. Uneven distribution of medical resources across regions affects treatment accessibility and coverage. Additionally, the high costs and complex management of therapies pose challenges for reimbursement systems and patient affordability. The lack of standardized treatment protocols and regulatory discrepancies further complicate cross-border product launches. Companies must carefully balance innovation breakthroughs with risk management to ensure stable market growth.Downstream demand for peanut allergy therapeutics is moving toward precision and comprehensive care management. With broader adoption of early screening technologies and increased public awareness, more potential patients will receive timely diagnosis and intervention, fostering wider use of immunotherapies. Collaboration among primary care physicians, allergy specialists, and school health programs will strengthen, promoting personalized and long-term treatment management. There is growing demand for safer, more convenient products, while digital health solutions and telemedicine support will become vital tools to enhance adherence and monitor treatment efficacy. Overall, the market is evolving into an integrated ecosystem encompassing diagnosis, therapy, and follow-up care.

This report aims to provide a comprehensive presentation of the global market for Peanut Allergy Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Peanut Allergy Therapeutics by region & country, by Type, and by Distribution Channel.

The Peanut Allergy Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peanut Allergy Therapeutics.

Market Segmentation

By Company

  • Viatris
  • Bayer
  • UCB Pharma
  • J & J
  • Perrigo
  • GSK
  • Kaleo
  • Amneal Pharma
  • ALK Abello
  • Aimmune Therapeutics
  • HUAPONT Pharm
  • Allergy Therapeutics
  • ASIT Biotech
  • Sanofi
  • DBV Technologies
  • HAL Allergy
  • Intrommune Therapeutics

Segment by Type

  • Epinephrine Injection
  • Antihistamines
  • Oral Immunotherapy
  • Other

Segment by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Peanut Allergy Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Peanut Allergy Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Peanut Allergy Therapeutics in country level. It provides sigmate data by Type, and by Distribution Channel for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Peanut Allergy Therapeutics Product Introduction
  • 1.2 Global Peanut Allergy Therapeutics Market Size Forecast (2020-2031)
  • 1.3 Peanut Allergy Therapeutics Market Trends & Drivers
    • 1.3.1 Peanut Allergy Therapeutics Industry Trends
    • 1.3.2 Peanut Allergy Therapeutics Market Drivers & Opportunity
    • 1.3.3 Peanut Allergy Therapeutics Market Challenges
    • 1.3.4 Peanut Allergy Therapeutics Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Peanut Allergy Therapeutics Players Revenue Ranking (2024)
  • 2.2 Global Peanut Allergy Therapeutics Revenue by Company (2020-2025)
  • 2.3 Key Companies Peanut Allergy Therapeutics Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Peanut Allergy Therapeutics Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Peanut Allergy Therapeutics
  • 2.6 Peanut Allergy Therapeutics Market Competitive Analysis
    • 2.6.1 Peanut Allergy Therapeutics Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Peanut Allergy Therapeutics Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peanut Allergy Therapeutics as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Epinephrine Injection
    • 3.1.2 Antihistamines
    • 3.1.3 Oral Immunotherapy
    • 3.1.4 Other
  • 3.2 Global Peanut Allergy Therapeutics Sales Value by Type
    • 3.2.1 Global Peanut Allergy Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Peanut Allergy Therapeutics Sales Value, by Type (2020-2031)
    • 3.2.3 Global Peanut Allergy Therapeutics Sales Value, by Type (%) (2020-2031)

4 Segmentation by Distribution Channel

  • 4.1 Introduction by Distribution Channel
    • 4.1.1 Hospital Pharmacy
    • 4.1.2 Retail Pharmacy
    • 4.1.3 Other
  • 4.2 Global Peanut Allergy Therapeutics Sales Value by Distribution Channel
    • 4.2.1 Global Peanut Allergy Therapeutics Sales Value by Distribution Channel (2020 VS 2024 VS 2031)
    • 4.2.2 Global Peanut Allergy Therapeutics Sales Value, by Distribution Channel (2020-2031)
    • 4.2.3 Global Peanut Allergy Therapeutics Sales Value, by Distribution Channel (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Peanut Allergy Therapeutics Sales Value by Region
    • 5.1.1 Global Peanut Allergy Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Peanut Allergy Therapeutics Sales Value by Region (2020-2025)
    • 5.1.3 Global Peanut Allergy Therapeutics Sales Value by Region (2026-2031)
    • 5.1.4 Global Peanut Allergy Therapeutics Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Peanut Allergy Therapeutics Sales Value, 2020-2031
    • 5.2.2 North America Peanut Allergy Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Peanut Allergy Therapeutics Sales Value, 2020-2031
    • 5.3.2 Europe Peanut Allergy Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Peanut Allergy Therapeutics Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Peanut Allergy Therapeutics Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Peanut Allergy Therapeutics Sales Value, 2020-2031
    • 5.5.2 South America Peanut Allergy Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Peanut Allergy Therapeutics Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Peanut Allergy Therapeutics Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Peanut Allergy Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Peanut Allergy Therapeutics Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Peanut Allergy Therapeutics Sales Value, 2020-2031
    • 6.3.2 United States Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Peanut Allergy Therapeutics Sales Value by Distribution Channel, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Peanut Allergy Therapeutics Sales Value, 2020-2031
    • 6.4.2 Europe Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Peanut Allergy Therapeutics Sales Value by Distribution Channel, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Peanut Allergy Therapeutics Sales Value, 2020-2031
    • 6.5.2 China Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Peanut Allergy Therapeutics Sales Value by Distribution Channel, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Peanut Allergy Therapeutics Sales Value, 2020-2031
    • 6.6.2 Japan Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Peanut Allergy Therapeutics Sales Value by Distribution Channel, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Peanut Allergy Therapeutics Sales Value, 2020-2031
    • 6.7.2 South Korea Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Peanut Allergy Therapeutics Sales Value by Distribution Channel, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Peanut Allergy Therapeutics Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Peanut Allergy Therapeutics Sales Value by Distribution Channel, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Peanut Allergy Therapeutics Sales Value, 2020-2031
    • 6.9.2 India Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Peanut Allergy Therapeutics Sales Value by Distribution Channel, 2024 VS 2031

7 Company Profiles

  • 7.1 Viatris
    • 7.1.1 Viatris Profile
    • 7.1.2 Viatris Main Business
    • 7.1.3 Viatris Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.1.4 Viatris Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Viatris Recent Developments
  • 7.2 Bayer
    • 7.2.1 Bayer Profile
    • 7.2.2 Bayer Main Business
    • 7.2.3 Bayer Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.2.4 Bayer Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Bayer Recent Developments
  • 7.3 UCB Pharma
    • 7.3.1 UCB Pharma Profile
    • 7.3.2 UCB Pharma Main Business
    • 7.3.3 UCB Pharma Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.3.4 UCB Pharma Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.3.5 UCB Pharma Recent Developments
  • 7.4 J & J
    • 7.4.1 J & J Profile
    • 7.4.2 J & J Main Business
    • 7.4.3 J & J Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.4.4 J & J Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.4.5 J & J Recent Developments
  • 7.5 Perrigo
    • 7.5.1 Perrigo Profile
    • 7.5.2 Perrigo Main Business
    • 7.5.3 Perrigo Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.5.4 Perrigo Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Perrigo Recent Developments
  • 7.6 GSK
    • 7.6.1 GSK Profile
    • 7.6.2 GSK Main Business
    • 7.6.3 GSK Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.6.4 GSK Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.6.5 GSK Recent Developments
  • 7.7 Kaleo
    • 7.7.1 Kaleo Profile
    • 7.7.2 Kaleo Main Business
    • 7.7.3 Kaleo Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.7.4 Kaleo Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Kaleo Recent Developments
  • 7.8 Amneal Pharma
    • 7.8.1 Amneal Pharma Profile
    • 7.8.2 Amneal Pharma Main Business
    • 7.8.3 Amneal Pharma Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.8.4 Amneal Pharma Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Amneal Pharma Recent Developments
  • 7.9 ALK Abello
    • 7.9.1 ALK Abello Profile
    • 7.9.2 ALK Abello Main Business
    • 7.9.3 ALK Abello Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.9.4 ALK Abello Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.9.5 ALK Abello Recent Developments
  • 7.10 Aimmune Therapeutics
    • 7.10.1 Aimmune Therapeutics Profile
    • 7.10.2 Aimmune Therapeutics Main Business
    • 7.10.3 Aimmune Therapeutics Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.10.4 Aimmune Therapeutics Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Aimmune Therapeutics Recent Developments
  • 7.11 HUAPONT Pharm
    • 7.11.1 HUAPONT Pharm Profile
    • 7.11.2 HUAPONT Pharm Main Business
    • 7.11.3 HUAPONT Pharm Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.11.4 HUAPONT Pharm Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.11.5 HUAPONT Pharm Recent Developments
  • 7.12 Allergy Therapeutics
    • 7.12.1 Allergy Therapeutics Profile
    • 7.12.2 Allergy Therapeutics Main Business
    • 7.12.3 Allergy Therapeutics Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.12.4 Allergy Therapeutics Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Allergy Therapeutics Recent Developments
  • 7.13 ASIT Biotech
    • 7.13.1 ASIT Biotech Profile
    • 7.13.2 ASIT Biotech Main Business
    • 7.13.3 ASIT Biotech Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.13.4 ASIT Biotech Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.13.5 ASIT Biotech Recent Developments
  • 7.14 Sanofi
    • 7.14.1 Sanofi Profile
    • 7.14.2 Sanofi Main Business
    • 7.14.3 Sanofi Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.14.4 Sanofi Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Sanofi Recent Developments
  • 7.15 DBV Technologies
    • 7.15.1 DBV Technologies Profile
    • 7.15.2 DBV Technologies Main Business
    • 7.15.3 DBV Technologies Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.15.4 DBV Technologies Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.15.5 DBV Technologies Recent Developments
  • 7.16 HAL Allergy
    • 7.16.1 HAL Allergy Profile
    • 7.16.2 HAL Allergy Main Business
    • 7.16.3 HAL Allergy Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.16.4 HAL Allergy Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.16.5 HAL Allergy Recent Developments
  • 7.17 Intrommune Therapeutics
    • 7.17.1 Intrommune Therapeutics Profile
    • 7.17.2 Intrommune Therapeutics Main Business
    • 7.17.3 Intrommune Therapeutics Peanut Allergy Therapeutics Products, Services and Solutions
    • 7.17.4 Intrommune Therapeutics Peanut Allergy Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.17.5 Intrommune Therapeutics Recent Developments

8 Industry Chain Analysis

  • 8.1 Peanut Allergy Therapeutics Industrial Chain
  • 8.2 Peanut Allergy Therapeutics Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Peanut Allergy Therapeutics Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Peanut Allergy Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Peanut Allergy Therapeutics Market Trends
  • Table 2. Peanut Allergy Therapeutics Market Drivers & Opportunity
  • Table 3. Peanut Allergy Therapeutics Market Challenges
  • Table 4. Peanut Allergy Therapeutics Market Restraints
  • Table 5. Global Peanut Allergy Therapeutics Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Peanut Allergy Therapeutics Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Peanut Allergy Therapeutics Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Peanut Allergy Therapeutics Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Peanut Allergy Therapeutics
  • Table 10. Global Peanut Allergy Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peanut Allergy Therapeutics as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Peanut Allergy Therapeutics Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Peanut Allergy Therapeutics Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Peanut Allergy Therapeutics Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Peanut Allergy Therapeutics Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Peanut Allergy Therapeutics Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Peanut Allergy Therapeutics Sales Value by Distribution Channel: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Peanut Allergy Therapeutics Sales Value by Distribution Channel (2020-2025) & (US$ Million)
  • Table 20. Global Peanut Allergy Therapeutics Sales Value by Distribution Channel (2026-2031) & (US$ Million)
  • Table 21. Global Peanut Allergy Therapeutics Sales Market Share in Value by Distribution Channel (2020-2025)
  • Table 22. Global Peanut Allergy Therapeutics Sales Market Share in Value by Distribution Channel (2026-2031)
  • Table 23. Global Peanut Allergy Therapeutics Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Peanut Allergy Therapeutics Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Peanut Allergy Therapeutics Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Peanut Allergy Therapeutics Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Peanut Allergy Therapeutics Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Peanut Allergy Therapeutics Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Peanut Allergy Therapeutics Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Peanut Allergy Therapeutics Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Viatris Basic Information List
  • Table 32. Viatris Description and Business Overview
  • Table 33. Viatris Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of Viatris (2020-2025)
  • Table 35. Viatris Recent Developments
  • Table 36. Bayer Basic Information List
  • Table 37. Bayer Description and Business Overview
  • Table 38. Bayer Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of Bayer (2020-2025)
  • Table 40. Bayer Recent Developments
  • Table 41. UCB Pharma Basic Information List
  • Table 42. UCB Pharma Description and Business Overview
  • Table 43. UCB Pharma Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of UCB Pharma (2020-2025)
  • Table 45. UCB Pharma Recent Developments
  • Table 46. J & J Basic Information List
  • Table 47. J & J Description and Business Overview
  • Table 48. J & J Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of J & J (2020-2025)
  • Table 50. J & J Recent Developments
  • Table 51. Perrigo Basic Information List
  • Table 52. Perrigo Description and Business Overview
  • Table 53. Perrigo Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of Perrigo (2020-2025)
  • Table 55. Perrigo Recent Developments
  • Table 56. GSK Basic Information List
  • Table 57. GSK Description and Business Overview
  • Table 58. GSK Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of GSK (2020-2025)
  • Table 60. GSK Recent Developments
  • Table 61. Kaleo Basic Information List
  • Table 62. Kaleo Description and Business Overview
  • Table 63. Kaleo Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of Kaleo (2020-2025)
  • Table 65. Kaleo Recent Developments
  • Table 66. Amneal Pharma Basic Information List
  • Table 67. Amneal Pharma Description and Business Overview
  • Table 68. Amneal Pharma Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of Amneal Pharma (2020-2025)
  • Table 70. Amneal Pharma Recent Developments
  • Table 71. ALK Abello Basic Information List
  • Table 72. ALK Abello Description and Business Overview
  • Table 73. ALK Abello Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of ALK Abello (2020-2025)
  • Table 75. ALK Abello Recent Developments
  • Table 76. Aimmune Therapeutics Basic Information List
  • Table 77. Aimmune Therapeutics Description and Business Overview
  • Table 78. Aimmune Therapeutics Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of Aimmune Therapeutics (2020-2025)
  • Table 80. Aimmune Therapeutics Recent Developments
  • Table 81. HUAPONT Pharm Basic Information List
  • Table 82. HUAPONT Pharm Description and Business Overview
  • Table 83. HUAPONT Pharm Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of HUAPONT Pharm (2020-2025)
  • Table 85. HUAPONT Pharm Recent Developments
  • Table 86. Allergy Therapeutics Basic Information List
  • Table 87. Allergy Therapeutics Description and Business Overview
  • Table 88. Allergy Therapeutics Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of Allergy Therapeutics (2020-2025)
  • Table 90. Allergy Therapeutics Recent Developments
  • Table 91. ASIT Biotech Basic Information List
  • Table 92. ASIT Biotech Description and Business Overview
  • Table 93. ASIT Biotech Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of ASIT Biotech (2020-2025)
  • Table 95. ASIT Biotech Recent Developments
  • Table 96. Sanofi Basic Information List
  • Table 97. Sanofi Description and Business Overview
  • Table 98. Sanofi Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of Sanofi (2020-2025)
  • Table 100. Sanofi Recent Developments
  • Table 101. DBV Technologies Basic Information List
  • Table 102. DBV Technologies Description and Business Overview
  • Table 103. DBV Technologies Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of DBV Technologies (2020-2025)
  • Table 105. DBV Technologies Recent Developments
  • Table 106. HAL Allergy Basic Information List
  • Table 107. HAL Allergy Description and Business Overview
  • Table 108. HAL Allergy Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 109. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of HAL Allergy (2020-2025)
  • Table 110. HAL Allergy Recent Developments
  • Table 111. Intrommune Therapeutics Basic Information List
  • Table 112. Intrommune Therapeutics Description and Business Overview
  • Table 113. Intrommune Therapeutics Peanut Allergy Therapeutics Products, Services and Solutions
  • Table 114. Revenue (US$ Million) in Peanut Allergy Therapeutics Business of Intrommune Therapeutics (2020-2025)
  • Table 115. Intrommune Therapeutics Recent Developments
  • Table 116. Key Raw Materials Lists
  • Table 117. Raw Materials Key Suppliers Lists
  • Table 118. Peanut Allergy Therapeutics Downstream Customers
  • Table 119. Peanut Allergy Therapeutics Distributors List
  • Table 120. Research Programs/Design for This Report
  • Table 121. Key Data Information from Secondary Sources
  • Table 122. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Peanut Allergy Therapeutics Product Picture
  • Figure 2. Global Peanut Allergy Therapeutics Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Peanut Allergy Therapeutics Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Peanut Allergy Therapeutics Report Years Considered
  • Figure 5. Global Peanut Allergy Therapeutics Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Peanut Allergy Therapeutics Revenue in 2024
  • Figure 7. Peanut Allergy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Epinephrine Injection Picture
  • Figure 9. Antihistamines Picture
  • Figure 10. Oral Immunotherapy Picture
  • Figure 11. Other Picture
  • Figure 12. Global Peanut Allergy Therapeutics Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 13. Global Peanut Allergy Therapeutics Sales Value Market Share by Type, 2024 & 2031
  • Figure 14. Product Picture of Hospital Pharmacy
  • Figure 15. Product Picture of Retail Pharmacy
  • Figure 16. Product Picture of Other
  • Figure 17. Global Peanut Allergy Therapeutics Sales Value by Distribution Channel (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Peanut Allergy Therapeutics Sales Value Market Share by Distribution Channel, 2024 & 2031
  • Figure 19. North America Peanut Allergy Therapeutics Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America Peanut Allergy Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe Peanut Allergy Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe Peanut Allergy Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific Peanut Allergy Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific Peanut Allergy Therapeutics Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America Peanut Allergy Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America Peanut Allergy Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa Peanut Allergy Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa Peanut Allergy Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions Peanut Allergy Therapeutics Sales Value (%), (2020-2031)
  • Figure 30. United States Peanut Allergy Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 32. United States Peanut Allergy Therapeutics Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 33. Europe Peanut Allergy Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 35. Europe Peanut Allergy Therapeutics Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 36. China Peanut Allergy Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 38. China Peanut Allergy Therapeutics Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 39. Japan Peanut Allergy Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 41. Japan Peanut Allergy Therapeutics Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 42. South Korea Peanut Allergy Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 44. South Korea Peanut Allergy Therapeutics Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 45. Southeast Asia Peanut Allergy Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Southeast Asia Peanut Allergy Therapeutics Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 48. India Peanut Allergy Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India Peanut Allergy Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 50. India Peanut Allergy Therapeutics Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 51. Peanut Allergy Therapeutics Industrial Chain
  • Figure 52. Peanut Allergy Therapeutics Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed